NAUTILUS BIOTECH SA Information

NAUTILUS BIOTECH S.A. (2000 – 2009) was a VC-backed French biotechnology company; with a fully own subsidiary in the US (Nautilus Technologies, 2006-2009). Nautilus developed and commercialized a pipeline of innovative and proprietary second-generation cell lines (for higher productivity) and therapeutic proteins (engineered for higher biological activity and bioavailability, long lasting and/or orally available. Products included engineered human interferon alpha, growth hormone, erythropoietin, interferon beta, interferon gamma and clotting factor IX. Licensees of Nautilus products were: Aventis Pasteur (today Sanofi Aventis), Wyeth Pharmaceuticals (today Pfizer), Serono (today Merck Serono), Creabilis and Hanall Pharmaceuticals. The two most advanced products were Belerofon® and Vitatropin®. Injectable long-lasting Belerofon completed a clinical phase I study in the USA. Oral Belerofon received IND approval form FDA. Oral Vitatropin® received IND approval from FDA. In 2009, Nautilus assets were sold to Hanall Pharmaceuticals (South Korea) and to Catalyst Biosciences (USA).